STAT3 Inhibitor WP1066

Phase 2Small molecule

STAT3 Inhibitor WP1066 is one of 3 small molecule programs targeting Glioblastoma, IDH-wildtype. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glioblastoma, IDH-WildtypeRecruiting

Glioblastoma, IDH-WildtypePhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Glioblastoma, IDH-Wildtype

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 2

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Phase 2

1 3

STAT3 Inhibitor WP1066

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Glioblastoma, IDH-Wildtype

NCT05879250

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01904123·8 enrolled

Glioblastoma, IDH-wildtype1 trial

A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Recruiting·NNorthwestern University·Phase 2·NCT05879250·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for STAT3 Inhibitor WP1066. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STAT3 Inhibitor WP1066 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STAT3 Inhibitor WP1066. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

STAT3 Inhibitor WP1066

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metastatic Melanoma1 trial

Glioblastoma, IDH-wildtype1 trial

References

Drug Info

Quick Facts

Related News